Clinical Trials Logo
  1. Home
  2. Muscle Invasive Bladder Cancer
  3. NCT04101812

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Muscle Invasive Bladder Cancer Clinical Trial

Official title:
A Non-randomized, Prospective Clinical Study of Pegylated Liposomal Doxorubicin and PD-1 in the Second-line Treatment of Relapse or Metastatic Muscle Invasive Bladder Cancer

Clinical Trial Summary

Despite primary surgical management of muscle invasive bladder cancer (MIBC) with radical cystectomy and pelvic lymphnode dissection, up to 50% of patients will eventually develop tumours at distant sites, owing to pre-existing disseminated occult micrometastases. The first line treatment for relapse or metastatic MIBC is gemcitabine and cisplatin. After the failure of first line treatment, second line chemotherapy drugs can be chosen from doxorubicin, docetaxel, pemetrexed, etc. This non-randomized, prospective study aims to explore the efficacy and safety of PEGylated liposomal doxorubicin and PD-1 in second line treatment of MIBC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04101812
Study type Interventional
Source Tianjin Medical University Second Hospital
Contact Haitao Wang
Phone (022)28331788
Email peterrock2000@126.com
Status Recruiting
Phase Phase 2
Start date September 17, 2019
Completion date May 31, 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02546661 - Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer Phase 1
Active, not recruiting NCT03732677 - Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC Phase 3
Terminated NCT02716896 - Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer N/A
Recruiting NCT04047693 - Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma Phase 2
Recruiting NCT02648100 - Basal Like Bladder Cancer : Signature and Therapeutic N/A
Terminated NCT03397394 - Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Phase 2
Recruiting NCT05236218 - To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).
Active, not recruiting NCT04730219 - Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma Phase 2
Completed NCT03294304 - BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy Phase 2
Completed NCT03773666 - A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Phase 1
Completed NCT01031420 - Dose Dense MVAC for Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT04813107 - A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT03747419 - Avelumab and Radiation in Muscle-Invasive Bladder Cancer Phase 2
Recruiting NCT04960709 - Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin Phase 3
Not yet recruiting NCT05860543 - Clinical Performance Evaluation of the C2i Test
Recruiting NCT05979740 - RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Phase 2
Active, not recruiting NCT04053101 - Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer